Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable ATP-dependent RNA helicase DDX28 is a member of the DEAD-box family of RNA helicases, characterized by the conserved DEAD motif (Asp-Glu-Ala-Asp). It is an enzyme with RNA-dependent ATPase and helicase activities, localized primarily in the mitochondrial matrix, where it plays an essential role in the biogenesis of the mitochondrial large ribosomal subunit (mt-LSU)[3]. DDX28 interacts directly with mitochondrial 16S rRNA, and its silencing leads to impaired mt-LSU assembly, reduced mitochondrial protein synthesis, and deficient assembly of oxidative phosphorylation complexes, resulting in compromised cellular respiration[1][3]. Its activity is indispensable for normal mitochondrial translation and energy metabolism. Mutations or deficiencies in DDX28 are associated with diseases such as Spastic Paraplegia 7 (autosomal recessive) and Perrault syndrome[3]. DDX28 is not currently considered a therapeutic target, and no interacting drugs or mechanisms of action for drug targeting are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX28 (DDX28).